Skip to content

New Psoriasis Drug Shows Promise in Trials

Clinical Trial Shows Efficacy of New Psoriasis Medication. Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients, said first author Kenneth Gordon, MD, professor in Dermatology. In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis. New drugs that block highly specific parts of the immune system are showing remarkable promise in treating two maddening skin diseases, eczema and psoriasis, according to papers published Wednesday in a leading medical journal. Beck, who is a paid consultant to the two companies, was the lead author of the paper on the drug, dupilumab, that was published in the New England Journal of Medicine. For psoriasis, a drug being developed by Novartis proved to be highly effective in late-stage clinical trials in clearing the skin of the characteristic patchy red plaques, according to another paper also published in the medical journal. Secukinumab for plaque psoriasis shows promise in trials. For the two phase III clinical trials of the drug secukinumab, which were sponsored by the drug’s producer Novartis Pharmaceuticals and described in an article published in the New England Journal of Medicine on July 9, results showed that the drug holds potential as treatment for people with moderate and severe plaque psoriasis. Fifty-nine percent of the subjects who received 300 mg of the drug also reported 90 percent improvement in their psoriasis symptoms and over 28 percent reported that their psoriasis has completely cleared up.

New Psoriasis Drug Shows Promise in Trials 2Psoriasis drug shows promise in diabetes trial. Alefacept is the first targeted biological drug assessed in patients with new-onset type 1 diabetes that significantly depleted the T cells which attack the pancreas in type 1 diabetes, while preserving other immune cells which are important for pancreatic function. New Drug Shows Promise Against Psoriasis. TUESDAY, June 16, 2015 (HealthDay News) — Many patients with the skin disease psoriasis showed significant improvement when taking an experimental drug called ixekizumab, according to a late-stage, phase 3 clinical trial. Secukinumab appears more effective than current popular treatment, study says More.

FDA-approved drugs show promise for rapid and robust hair regrowth. Applying the JAK drugs to the skin of bald mice over five days saw them grow new hair within 10 days, while the control group that went untreated remained bald. The scientists say they have already begun research in this area with clinical trials underway for the two drugs for treatment of plaque psoriasis and alopecia areata. England Journal of Medicine article Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. Secukinumab, a new monoclonal psoriasis drug has shown promise in two phase 3 clinical trials were it was more efficient than currently available treatments.

Psoriasis Drug Shows Promise In Diabetes Trial

An experimental drug AEB071 could be an effective novel treatment for psoriasis and other autoimmune diseases, early research in humans indicates (Journal of Clinical Investigation, 7 August 2008). Novel psoriasis drug shows promise. Developing new psoriasis treatment regimens for patients based on their clinical profile. Clinical trials and tribulations. A drug developed from the toxin of a sea anemone to treat autoimmune diseases like psoriasis and multiple sclerosis, showed promise in a phase 1 clinical trial. Drug Derived From Sea Anemone Shows Promise Against Psoriasis, MS. Must reads about the latest news and trends in healthcare careers. II trials with its drug PH-10 for patients with atopic dermatitis and psoriasis. Novel Drug From Nature Shows Early Promise. The medication is intended to treat autoimmune disorders such as psoriasis and MS. Anti-Interleukin 17 Agents Show Promise for Psoriasis in Clinical Trials. Tumor necrosis factor-alpha (TNF- ) inhibitors and anti-interleukin 12/23 (IL-12 and IL-23) therapies are the two classes of biologic drugs currently approved by the FDA for psoriasis.1 Among the other biologics in development, there are several anti-interleukin 17 (IL-17) agents that have shown significant promise in recent Phase II trials. In the New England Journal of Medicine article on the study, the researchers write: Taken together, these data suggest that inhibition of interleukin-17 may be an effective and targeted therapy for psoriasis.

Fda-approved Drugs Show Promise For Rapid And Robust Hair Regrowth

The oral A3 adenosine receptor agonist CF1-1 shows promise as a potential first-line systemic therapy for moderate to severe plaque psoriasis. EADV: New oral psoriasis drug shows excellent safety. Planning is underway for a pivotal phase III trial of CF101 in psoriasis, which is also being organized for CF101 in rheumatoid arthritis on the strength of favorable phase II findings, according to Dr. A phase II clinical trial led by Northwestern Medicine investigators shows that a new psoriasis drug called guselkumab has greater efficacy than the current standard of care for the chronic skin condition. Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients, said first author Kenneth Gordon, MD, professor in Dermatology. An ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.